Operating Advisory Board
He is also an entrepreneur, having founded several companies and exited two in the healthcare space. He has also been involved in many fund raising and licensing deals across the globe.
Raj founded Wizzcare Home Health Solutions, a pioneer in home care and tele-health company in India, which was sold to Indian’s leading E-health business. He is also a co-founder of Health Start, India’s first Healthcare accelerator. The accelerator has invested extensively in portfolio health companies, and Raj is an active board member and mentor to some of them.
He is a post graduate from the London University and executive programs from Harvard Business School and INSEAD, as well as an Accredited Executive Coach of the International Coaching Federation.
Market Research and Strategy Advisor
Previously, he worked as a grant manager for 4 years at the biotechnology firm AB-Biotics, a probiotics and pharmacogenetics company in the field of neurospiquiatría, obtaining financing for the development of their projects, and accompanying it from its initial stages until the exit to the alternative stock market. He has also worked as a consultant in the Euro-Funding firm, specialized in obtaining public funds for business development projects.
NewsAbility Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
NewsAbility Pharmaceuticals launches a new updated website with a fresh design + info
NewsAbility Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
NewsAbility Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
NewsAbility Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
NewsAbility Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
NewsAbility Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
NewsABILITY PHARMACEUTICALS Initiates Clinical Trial with its Dual mTORC1/C2 Inhibitor ABTL0812 in Patients with Lung and Pancreatic Cancer + info
NewsAbility Pharmaceuticals to Present at the 6th Annual European Life Sciences CEO Forum in Zurich, March 5-6, 2013. + info